Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One needle to rule them all: new dialysis device aims to simplify treatment

NCT ID NCT07599085

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new device that lets dialysis patients use just one needle instead of two for their blood cleaning treatments. The goal is to see if it is safe and works well for people who already have a mature vein connection (fistula). About 20 adults who need dialysis three times a week will try the device over 30 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is an adult patient ≥ 18 years of age. 2. Subject with the ability to attend "in-center" hemodialysis. 3. Subject has a requirement of hemodialysis 3 times/week. 4. Subject has an AVF that was determined to be mature by standard clinical definition 5. Subject with ≥ 3 months stable in center hemodialysis with \>90 days use of an AV fistula cannulated with 2 needles with no evidence of stenosis or thrombosis. 6. Subject has an AVF that meets all of the following Rule of 5s: * Flow ≥ 500 mL/min * Diameter ≥ 5 mm * Depth ≤ 5 mm from the skin surface * Length ≥ 5 cm usable for cannulation 7. Subject does not have any established lesions or stents in the access circuit as confirmed by ultrasound. 8. Subject dialyzes at a center that can confirm 30-day data collection on cannulations and is willing to cooperate in performing real-time assessments and record keeping per Sponsor requirements, to assure subject safety requirements. Exclusion Criteria: 1. Subject has an existing arteriovenous graft. 2. Subject has any active infection within the past 90 days. 3. Subject is currently receiving or planning home hemodialysis. 4. Subject has a distorted anatomy and/or local vascular injury. 5. Subject has a change in blood thinner regimen in the last 60 days. 6. Subject has any unstable medical or psychiatric conditions likely to impair their ability to participate in the study. 7. Subject has a known history of clinically significant IV drug use. 8. Subject is a pregnant or nursing woman, or anticipates pregnancy in the next 3 months. 9. Subject is enrolled in another study that could confound the results of this study, without documented pre-approval. 10. Subject has a known allergy to plastics. 11. Subject is unwilling to sign the study's consent form. 12. Subject has a life expectancy of less than 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.